Primary ciliary dyskinesia: A multicenter survey on clinical practice and patient management in Italy

IntroductionThere are no recent data on primary ciliary dyskinesia (PCD) distribution, diagnosis and treatment in Italy. MethodsA descriptive study based on a survey questionnaire. It consisted of three sections (patients, diagnosis, and treatment), and sent to all the Italian PCD Centers. ResultsQuestionnaires obtained from 20/22 centers in 12/20 regions showed that the total number of PCD patients treated at the participating centers was of 416. Out of all centers, 55% follow <20 patients, two centers have >40 patients, and 75% follow both pediatric and adults. Age at diagnosis was between 4 and 8 years in 45% of the centers, <3 years in three centers. Nasal nitric oxide, transmission electron microscopy and ciliary high-speed video microscopy are performed in 75%, 90%, and 40% of centers, respectively. Immunofluorescence is available in five centers. Genetic analysis is offered in 55% of the centers, and in seven centers >50% of the patients have a known genetic profile. Patients treated at all centers receive inhaled saline solutions, corticosteroids and chest physiotherapy. Prophylactic antibiotics and mucolytics are prescribed in 95% and 50% of the centers, respectively. Pseudomonas infection is treated with oral or inhaled antibiotics. ConclusionsMany Italian centers care for a small number of pediatric and adult patients, and diagnosis is often delayed. We found a great variability in the available diagnostic procedures, as well in the prescribed therapies. Our study will help to uniform diagnostic algorithm and share treatments protocols for PCD in Italy and allowed to set specific national goals.

Automated summary

A survey conducted in Italy found that there are 20 centers providing diagnosis and treatment for primary ciliary dyskinesia (PCD), with a total of 416 patients being treated. The study revealed that there is a great variability in diagnostic procedures and prescribed therapies, highlighting the need for standardization and sharing of treatment protocols. The results will help set specific national goals for PCD in Italy.